Myeloablative Radioligand Therapy Targeting C-X-C Motif Chemokine Receptor 4 in Advanced Multiple Myeloma

Scientists determined the myeloablative efficacy of C-X-C motif chemokine receptor 4 (CXCR4) radioligand therapy in multiple myeloma patients and assessed the safety profile of this treatment.